Literature DB >> 21498658

Structural basis for the high-affinity inhibition of mammalian membranous adenylyl cyclase by 2',3'-o-(N-methylanthraniloyl)-inosine 5'-triphosphate.

Melanie Hübner1, Anshuman Dixit, Tung-Chung Mou, Gerald H Lushington, Cibele Pinto, Andreas Gille, Jens Geduhn, Burkhard König, Stephen R Sprang, Roland Seifert.   

Abstract

2',3'-O-(N-Methylanthraniloyl)-ITP (MANT-ITP) is the most potent inhibitor of mammalian membranous adenylyl cyclase (mAC) 5 (AC5, K(i), 1 nM) yet discovered and surpasses the potency of MANT-GTP by 55-fold (J Pharmacol Exp Ther 329:1156-1165, 2009). AC5 inhibitors may be valuable drugs for treatment of heart failure. The aim of this study was to elucidate the structural basis for the high-affinity inhibition of mAC by MANT-ITP. MANT-ITP was a considerably more potent inhibitor of the purified catalytic domains VC1 and IIC2 of mAC than MANT-GTP (K(i), 0.7 versus 18 nM). Moreover, there was considerably more efficient fluorescence resonance energy transfer between Trp1020 of IIC2 and the MANT group of MANT-ITP compared with MANT-GTP, indicating optimal interaction of the MANT group of MANT-ITP with the hydrophobic pocket. The crystal structure of MANT-ITP in complex with the G(s)α- and forskolin-activated catalytic domains VC1:IIC2 compared with the existing MANT-GTP crystal structure revealed only subtle differences in binding mode. The higher affinity of MANT-ITP to mAC compared with MANT-GTP is probably due to fewer stereochemical constraints upon the nucleotide base in the purine binding pocket, allowing a stronger interaction with the hydrophobic regions of IIC2 domain, as assessed by fluorescence spectroscopy. Stronger interaction is also achieved in the phosphate-binding site. The triphosphate group of MANT-ITP exhibits better metal coordination than the triphosphate group of MANT-GTP, as confirmed by molecular dynamics simulations. Collectively, the subtle differences in ligand structure have profound effects on affinity for mAC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21498658      PMCID: PMC3127541          DOI: 10.1124/mol.111.071894

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  32 in total

Review 1.  Generalized born models of macromolecular solvation effects.

Authors:  D Bashford; D A Case
Journal:  Annu Rev Phys Chem       Date:  2000       Impact factor: 12.703

2.  GDP affinity and order state of the catalytic site are critical for function of xanthine nucleotide-selective Galphas proteins.

Authors:  Andreas Gille; Katharina Wenzel-Seifert; Michael B Doughty; Roland Seifert
Journal:  J Biol Chem       Date:  2002-12-23       Impact factor: 5.157

3.  A conformational transition in the adenylyl cyclase catalytic site yields different binding modes for ribosyl-modified and unmodified nucleotide inhibitors.

Authors:  Jenna L Wang; Jian-Xin Guo; Qi-Yuan Zhang; Jay J-Q Wu; Roland Seifert; Gerald H Lushington
Journal:  Bioorg Med Chem       Date:  2007-02-11       Impact factor: 3.641

4.  Structural basis for the inhibition of mammalian membrane adenylyl cyclase by 2 '(3')-O-(N-Methylanthraniloyl)-guanosine 5 '-triphosphate.

Authors:  Tung-Chung Mou; Andreas Gille; David A Fancy; Roland Seifert; Stephen R Sprang
Journal:  J Biol Chem       Date:  2004-12-09       Impact factor: 5.157

5.  Differential interactions of G-proteins and adenylyl cyclase with nucleoside 5'-triphosphates, nucleoside 5'-[gamma-thio]triphosphates and nucleoside 5'-[beta,gamma-imido]triphosphates.

Authors:  Andreas Gille; Jianxin Guo; Tung-Chung Mou; Michael B Doughty; Gerald H Lushington; Roland Seifert
Journal:  Biochem Pharmacol       Date:  2005-11-04       Impact factor: 5.858

6.  Broad specificity of mammalian adenylyl cyclase for interaction with 2',3'-substituted purine- and pyrimidine nucleotide inhibitors.

Authors:  Tung-Chung Mou; Andreas Gille; Srividya Suryanarayana; Mark Richter; Roland Seifert; Stephen R Sprang
Journal:  Mol Pharmacol       Date:  2006-06-09       Impact factor: 4.436

7.  Effects of guanine, inosine, and xanthine nucleotides on beta(2)-adrenergic receptor/G(s) interactions: evidence for multiple receptor conformations.

Authors:  R Seifert; U Gether; K Wenzel-Seifert; B K Kobilka
Journal:  Mol Pharmacol       Date:  1999-08       Impact factor: 4.436

Review 8.  New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: effects of targeted disruption of the type 5 adenylyl cyclase gene.

Authors:  Satoshi Okumura; Sayaka Suzuki; Yoshihiro Ishikawa
Journal:  J Pharmacol Sci       Date:  2009-03-07       Impact factor: 3.337

9.  Adenylyl cyclase 5: a new clue in the search for the "fountain of youth"?

Authors:  Julia A Chester; Val J Watts
Journal:  Sci STKE       Date:  2007-11-20

10.  2'(3')-O-(N-methylanthraniloyl)-substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors.

Authors:  Andreas Gille; Roland Seifert
Journal:  J Biol Chem       Date:  2003-02-03       Impact factor: 5.157

View more
  5 in total

1.  Inhibition of the adenylyl cyclase toxin, edema factor, from Bacillus anthracis by a series of 18 mono- and bis-(M)ANT-substituted nucleoside 5'-triphosphates.

Authors:  Hesham Taha; Stefan Dove; Jens Geduhn; Burkhard König; Yuequan Shen; Wei-Jen Tang; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-24       Impact factor: 3.000

2.  Structure-activity relationships for the interactions of 2'- and 3'-(O)-(N-methyl)anthraniloyl-substituted purine and pyrimidine nucleotides with mammalian adenylyl cyclases.

Authors:  Cibele Pinto; Gerald H Lushington; Mark Richter; Andreas Gille; Jens Geduhn; Burkhard König; Tung-Chung Mou; Stephen R Sprang; Roland Seifert
Journal:  Biochem Pharmacol       Date:  2011-05-18       Impact factor: 5.858

Review 3.  Inhibitors of membranous adenylyl cyclases.

Authors:  Roland Seifert; Gerald H Lushington; Tung-Chung Mou; Andreas Gille; Stephen R Sprang
Journal:  Trends Pharmacol Sci       Date:  2011-11-17       Impact factor: 14.819

Review 4.  International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.

Authors:  Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

5.  Role of the nucleotidyl cyclase helical domain in catalytically active dimer formation.

Authors:  Irene Vercellino; Lenka Rezabkova; Vincent Olieric; Yevhen Polyhach; Tobias Weinert; Richard A Kammerer; Gunnar Jeschke; Volodymyr M Korkhov
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-30       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.